Trade name | Drug/Bioactives | Target tissue | Target indication (Use) | Delivery system | Route | FDA Approval Status | Refs. | |
---|---|---|---|---|---|---|---|---|
Durezol® | Difluprednate Ophthalmic Emulsion 0.05% | Mainly anterior segment of the eye, anterior chamber, cornea conjunctiva | Anterior uveitis | Nanoemulsion | Eye drop | Approved | [274] | |
Restasis® | Cyclosporine ophthalmic emulsion 0.05% | Cornea and Tear film | Dry eye | Nanoemulsion | Oral, intravenous (IV), eye drop | Approved | [275] | |
Ikervis® | Ciclosporin ophthalmic emulsion 0.1% | Cornea and Tear film | Dry eye | Nanoemulsion | Eye drop | Approved | [276] | |
Cequa® | Cyclosporine ophthalmic solution 0.09% | Cornea and Tear film | Dry eye | Micelle | Eye drop | Approved | [277] | |
Cyclokat® | Cationic emulsion 0.1% | Cornea and Tear film | Dry eye | Cationic nanoemulsion | Eye drop | Approved | [278] | |
Lacrisek® | Vitamin A palmitate, vitamin E | Cornea and Tear film | Dry eye | Liposomal spray | Eye drop | Approved | [279] | |
Artelac Rebalance® | Lubricant | Cornea and Tear film | Dry eye | Liposomal eyedrops | Eye drop | Approved | [280] | |
Ozurdex | Dexamethasone biodegradable implant | Vitreous, Retina, Choroid | Macular edema, Non-infectious uveitis | Implant | Intravitreal injection | Approved | [235] | |
Iluvien | Fluocinolone acetonide nonbiodegradable implant | Vitreous, Retina, Choroid | Diabetic macular edema | Implant | Intravitreal injection | Approved | [236] | |
Visudyne | Verteporfin | Retina, Choroid | Wet AMD, Choroidal neovascularization, Central Serous Chorioretinopathy | Liposomal injection | Intravenous | Approved | [281] | |
Macugen® | Pegaptanib | Retina Choroid | Wet AMD | Liposome | Intravitreal injection | Approved | [282] | |
Triesence | Triamcinolone acetonide suspension | Vitreous, Retina, Choroid | Macular edema | Microparticle | Intravitreal injection | Approved | ||
AzaSite ® | Azithromycin Ophthalmic 1% Solution | Conjunctiva, cornea | Antimicrobial | Micelle | Eye drop | Approved | [283] | |
Trivaris | Triamcinolone acetonide suspension | Vitreous, Retina, Choroid | Uveitis | Microparticle | Intravitreal injection | Approved | ||
Kenalog | Triamcinolone acetonide suspension | Vitreous, Retina, Choroid | Macular edema | Microparticle | Intravitreal injection, Suprachoroidal injection | Approved | ||
Retisert | Fluocinolone acetonide nonbiodegradable implant | Vitreous, Retina, Choroid | Uveitis | Implant | Intravitreal injection | Approved | [238] | |
TLC399 | ProDex | Vitreous, Retina, Choroid | Macular edema | Pro Dex | Intravitreal injection | Phase II | [239] | |
POLAT-001 | latanoprost-coated liposome | Anterior segment | Glaucoma | Liposome | Subconjunctival injection | Phase II | [284] | |
SYSTANE® | Propylene glycol-based nanoemulsion | Cornea and Tear film | Dry eye | Nanoemulsion | Eye drop | Phase IV | [285] | |
ENV 515 | Travoprost extended release (XR) | Anterior segment | Glaucoma | Nanoparticles | Intracameral Implant | Phase II | [286] | |
AR-13503 | AR-13503 implant alone and in combination with aflibercept | Retina, Choroid | Neovascular AMD and diabetic macular edema | Intravitreal implants | Intravitreal injection | Phase I | ||
AR-1105 | Dexamethasone intravitreal implant | Retina, Choroid | AMD and diabetic macular edema | Intravitreal implants | Intravitreal injection | Phase II | [3] | |
Taxol | Paclitaxel albumin-stabilized nanoparticle formulation | Retina, Choroid | Intraocular melanoma | Nanoparticles | Intravenous injection | Phase II | [241] | |
GB-102 | Sunitinib malate | Retina, Choroid | AMD | Nanoparticles | Intravitreal injection | Phase I | [242] | |
KPI-121 | 1 and 0.25% loteprednol etabonate | Anterior segment | Conjunctiva, cornea, tear film | Mucus penetrating particles | Eye drop | Phase III | [243] | |
OCS-01 | Dexamethasone Cylcodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/ml | Anterior segment, Retina | Control of Inflammation, Diabetic Macular Edema | Nanoparticle | Eye drop | Phase II | [244] |